about

Group Overview

With a 160-year heritage, Aspen is a leading global specialty and branded multinational pharmaceutical company in both emerging and developed markets with approximately 10 000 employees at 70 established business operations in 55 countries.

We improve the health of patients in more than 150 countries through our high quality, affordable and effective healthcare solutions. Our key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands that include Anaesthetics and Thrombosis products.

Our manufacturing capabilities are scaleable to demand and cover a wide variety of product types including injectables, oral solid dose, liquids, semi-solids, steriles, biologicals and active pharmaceutical ingredients. We operate 23 manufacturing facilities across 15 sites and we hold international manufacturing approvals from some of the most stringent global regulatory agencies listed here including, among others, the United States Food and Drug Administration, the Australian Therapeutic Goods Administration and the European Directorate for the Quality of Medicines.

Click here to download our corporate presentation.

We operate with an established business presence in 55 countries and supply products in more than 150 countries.

Quick Facts

Established: 1850
Employees: Approximately 10 000
Share code: APN
JSE: Listed in 1998

Board of Directors

Stephen Saad (55)

Stephen Saad (55)

Qualification:
CA(SA), PhD (Commerce) Honoris Causa
Appointment: January 1999
Classification: Executive director

Gus Attridge (58)

Gus Attridge (58)

Qualification:
 CA(SA)
Appointment: January 1999
Classification: Executive director

Kuseni Dlamini (51)

Kuseni Dlamini (51)

Qualification:
 MPhil (Oxon), BSocSci (Hons), (Natal) (see full CV's)
Appointment: April 2012
Classification: Independent non-executive, Chairman

Linda de Beer (50)

Linda de Beer (50)

Qualification: 
CA(SA), MCom (Tax), CD(SA)
Appointment: July 2018
Classification: Independent non-executive

Ben Kruger (60)

Ben Kruger (60)

Qualification: 
CA(SA), Advanced Programme in Management (Harvard Business School)
Appointment: April 2019
Classification: Lead Independent non-executive

Themba Mkhwanazi (50)

Themba Mkhwanazi (50)

Qualification: 
B.Eng (Hons)
Appointment: July 2018
Classification: Independent non-executive

Chris Mortimer (58)

Chris Mortimer (58)

Qualification: 
BA, LLB
Appointment: January 1999
Classification: Non-executive

Babalwa Ngonyama (45)

Babalwa Ngonyama (45)

Qualification:
 CA(SA), MBA, Higher Diploma in Banking Law (RAU)
Appointment: April 2016
Classification: Independent non-executive

David Redfern (53)

David Redfern (53)

Qualification: 
BSc (Hons), CA
Appointment: February 2015
Classification:Non-executive (British)

Sindi Zilwa (52)

Sindi Zilwa (52)

Qualification:
 CA(SA), CDSA, Advanced Taxation (UNISA) Certificate (see CV's)
Appointment: September 2006
Classification: Independent non-executive

Our business segments

We focus on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through our key business segments:

Commercial Pharmaceuticals

Contribution to Group revenue

Regional Brands – a widely diverse segment comprising predominantly leading domestic brands in the Sub-Saharan Africa, Australasia and Latin American territories.

Contribution to Group revenue

46%

Sterile Focus Brands – focused on niche, sterile products comprising our Anaesthetics Brands and Thrombosis Brands.

Anaesthetics – includes a broad range of general anaesthetics, muscle relaxants as well as a number of local anaesthetics including topical agents.

Thrombosis – comprises a broad range of specialist injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors and heparin derivatives.

Contribution to Group revenue

39%

Manufacturing

Contract and supply of chemical and biochemical APIs and finished dose form (“FDF”) pharmaceuticals for third parties

Contribution to Group revenue

15%